BTIG raised the firm’s price target on Arcturus Therapeutics (ARCT) to $48 from $41 and keeps a Buy rating on the shares. The Kostaive ...
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Average Target Price from Analysts
Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The firm has a 50-day simple moving average of $17.00 and a 200 day simple moving average of $18.89.
Jonathan Edelman, senior vice president of CSL’s vaccines innovation unit, said the approval “marks a significant milestone” ...
Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...
2d
GlobalData on MSNJapan’s MHLW approves CSL Behring’s Andembry to stop HAE attacksCSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Also in Europe, officials signed off on CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine, Kostaive, for use in individuals ages 18 and older. The approval is based on results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results